BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28844540)

  • 21. Mutational profiling of acral melanomas in Korean populations.
    Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
    Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of hotspot mutations in BRAF, NRAS, and KIT genes in primary meningeal melanocytic tumors of intermediate grade.
    Kim YJ; Müller CS; Bohle RM
    Clin Neuropathol; 2016; 35(3):151-3. PubMed ID: 26784966
    [No Abstract]   [Full Text] [Related]  

  • 24. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
    Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.
    Lasota J; Kowalik A; Felisiak-Golabek A; Zięba S; Waloszczyk P; Masiuk M; Wejman J; Szumilo J; Miettinen M
    Mod Pathol; 2019 Jul; 32(7):957-966. PubMed ID: 30760858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutations might be more common than supposed in vulvar melanomas.
    Wylomanski S; Denis MG; Théoleyre S; Bouquin R; Vallée A; Knol AC; Saint-Jean M; Peuvrel L; Dréno B; Quéreux G
    Exp Dermatol; 2018 Feb; 27(2):210-213. PubMed ID: 29178146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Hou JY; Baptiste C; Hombalegowda RB; Tergas AI; Feldman R; Jones NL; Chatterjee-Paer S; Bus-Kwolfski A; Wright JD; Burke WM
    Cancer; 2017 Apr; 123(8):1333-1344. PubMed ID: 28026870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
    Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
    [No Abstract]   [Full Text] [Related]  

  • 31. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.
    Dias-Santagata D; Selim MA; Su Y; Peng Y; Vollmer R; Chłopik A; Tell-Marti G; Paral KM; Shalin SC; Shea CR; Puig S; Fernandez-Figueras MT; Biernat W; Ryś J; Marszalek A; Hoang MP
    Br J Dermatol; 2017 Nov; 177(5):1376-1384. PubMed ID: 28734009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melanocytomas of the central nervous system: a clinicopathological and molecular study.
    Wang H; Zhang S; Wu C; Zhang Z; Qin T
    Eur J Clin Invest; 2013 Aug; 43(8):809-15. PubMed ID: 23683178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.
    Mikkelsen LH; Larsen AC; von Buchwald C; Drzewiecki KT; Prause JU; Heegaard S
    APMIS; 2016 Jun; 124(6):475-86. PubMed ID: 27004972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
    Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
    J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
    Shoushtari AN; Bluth MJ; Goldman DA; Bitas C; Lefkowitz RA; Postow MA; Munhoz RR; Buchar G; Hester RH; Romero JA; Fitzpatrick LJ; Weiser MR; Panageas KS; Wolchok JD; Chapman PB; Carvajal RD
    Melanoma Res; 2017 Feb; 27(1):57-64. PubMed ID: 27792058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases.
    Cinotti E; Chevallier J; Labeille B; Cambazard F; Thomas L; Balme B; Leccia MT; D'Incan M; Vercherin P; Douchet C; Rubegni P; Perrot JL
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1834-1840. PubMed ID: 28543798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.